We acknowledge that the weak correlation between STIM1 and ORAI1 polymorphisms and the risk of HCC progression in CHB patients may be due to the modest sample size (3631 CHB patients), which led to the reduced power of the statistical analysis. Here, ORAI1 is linked to hepatocellular carcinoma.